• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

YOHIMBINE Drug Record

  • Summary
  • Interactions
  • Claims
  • YOHIMBINE chembl:CHEMBL15245 Approved

    Alternate Names:

    YOHIMBINE
    17ALPHA-HYDROXYYOHIMBAN-16ALPHA-CARBOXYLIC ACID METHYL ESTER
    QUEBRACHINE
    ACTIBINE®
    JOHIMBIN
    YOHIMBIN
    YOHIMBIC ACID METHYL ESTER
    QUEBRACHIN
    CORYNINE
    (16ALPHA,17ALPHA)-17-HYDROXYYOHIMBAN-16-CARBOXYLIC ACID METHYL ESTER
    APHRODINE
    (+)-YOHIMBINE
    chemidplus:146-48-5
    chembl:CHEMBL15245
    pubchem.compound:8969
    rxcui:220982
    drugbank:01392

    Drug Info:

    Drug Class anti-impotence agents
    Drug Class mydriatics
    Year of Approval not approved by the fda
    FDA Approval not approved by the FDA
    Drug Class small molecule
    Drug Indications Anti-impotence Agents
    Drug Indications Mydriatics
    (2 More Sources)

    Publications:

    Cleary et al., 2002, Investigation of neurotransmission in vas deferens from alpha(2A/D)-adrenoceptor knockout mice., Br. J. Pharmacol.
    Rizzo et al., 2001, Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein., Eur. J. Pharmacol.
    Kalkman et al., 2003, alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs., Eur. J. Pharmacol.
    Lalchandani et al., 2002, Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype., J. Pharmacol. Exp. Ther.
    Millan et al., 2000, Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states., Synapse
    Cleary et al., 2005, The alpha (1D)-adrenoceptor antagonist BMY 7378 is also an alpha (2C)-adrenoceptor antagonist., Auton Autacoid Pharmacol
    Zádori et al., 2007, Pre- and postsynaptic mechanisms in the clonidine- and oxymetazoline-induced inhibition of gastric motility in the rat., Neurochem. Int.
    Laurila et al., 2007, The second extracellular loop of alpha2A-adrenoceptors contributes to the binding of yohimbine analogues., Br. J. Pharmacol.
    Ozdoğan et al., 2006, The analgesic efficacy of partial opioid agonists is increased in mice with targeted inactivation of the alpha2A-adrenoceptor gene., Eur. J. Pharmacol.
    Paul et al., 1999, Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors., J. Biol. Chem.
    Vilardaga JP et al., 2005, Molecular basis of inverse agonism in a G protein-coupled receptor., Nat Chem Biol
    Gyires et al., 2000, Functional evidence that gastroprotection can be induced by activation of central alpha(2B)-adrenoceptor subtypes in the rat., Eur. J. Pharmacol.
    Takada et al., 2002, Meperidine exerts agonist activity at the alpha(2B)-adrenoceptor subtype., Anesthesiology
    Freitag et al., 1996, Adrenoceptor- and cholinoceptor-mediated mechanisms in the regulation of 5-hydroxytryptamine release from isolated tracheae of newborn rabbits., Br. J. Pharmacol.
    Alonso et al., 2007, Yohimbine prevents morphine-induced changes of glial fibrillary acidic protein in brainstem and alpha2-adrenoceptor gene expression in hippocampus., Neurosci. Lett.
    Le Corre P et al., 2004, Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism., Clin Pharmacol Ther
  • YOHIMBINE   ADRA2B

    Interaction Score: 1.89

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12110610 10822066 12170055 8872361 10611634 17123717


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • YOHIMBINE   ADRA2A

    Interaction Score: 1.74

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17664022 17558432 16325800 12591093 10506165 10611634 16407989


    Sources:
    DTC TdgClinicalTrial TEND PharmGKB TTD

  • YOHIMBINE   ADRA2C

    Interaction Score: 1.5

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12110610 11226402 12591093 12438517 10611634 16176444


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • YOHIMBINE   DRD1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • YOHIMBINE   CYP2D6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15289791


    Sources:
    PharmGKB

  • YOHIMBINE   EHMT2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: YOHIMBINE

    • Version: 01-August-2011

    Alternate Names:
    YOHIMBINE Primary Drug Name

    Drug Info:
    Year of Approval not approved by the fda
    Drug Class mydriatics
    Drug Class anti-impotence agents

    Publications:

  • TdgClinicalTrial: YOHIMBINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Mydriatics
    Drug Indications Anti-impotence Agents
    Drug Class small molecule

    Publications:

  • DTC: YOHIMBINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL15245 ChEMBL Drug ID

    Drug Info:

    Publications:
    Vilardaga JP et al., 2005, Molecular basis of inverse agonism in a G protein-coupled receptor., Nat Chem Biol

  • PharmGKB: yohimbine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Le Corre P et al., 2004, Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism., Clin Pharmacol Ther

  • TTD: Yohimbine

    • Version: 2020.06.01

    Alternate Names:
    D0H4JM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL15245

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21